Scholars@Duke
Herbert Pang

Herbert Pang

Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
herbert.pang@duke.edu
Duke Box 2721, Durham, NC 27710
2424 Erwin Road Ste 1102, 11107 Hock Plaza, Durham, NC 27705

Scholarly Works - Conferences

Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).

Conference Journal of Clinical Oncology · January 20, 2015 306 Background: CALGB 80303 evaluated gemcitabine (G) in combination with either B or placebo (P) in 602 patients (pts) with APC. No significant difference in overall survival (OS) between treatment arms was observed. Previously, ... Full text Cite

Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.

Conference Hepatology · April 2014 UNLABELLED: Estrogens inhibit stellate cell activation and fibrogenesis. Thus, gender and reproductive states may influence the degree of fibrosis in patients with nonalcoholic steatohepatitis (NASH). To investigate the association between gender, menopaus ... Full text Link to item Cite

Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).

Conference Journal of Clinical Oncology · January 20, 2014 448 Background: Previously, we identified potential predictive biomarkers of C sensitivity related to EGFR signaling from archived tumor tissue from CALGB 80203. Due to the fact that blood-based markers are more convenient and ca ... Full text Cite

Abstract 4707: Validation of survival prognostic models for non-small-cell lung cancer instage- and age-specific groups.

Conference Cancer Research · April 15, 2013 AbstractAims: Performance status (PS) is commonly used for patient stratification in lung cancer clinical trials. Many prognostic models have been proposed to predict survival for non-small-cell lung cancer ... Full text Cite

CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).

Conference Journal of Clinical Oncology · June 20, 2012 CRA9013 Background: CALGB 170601 was a randomized, placebo-controlled phase III trial to determine whether duloxetine reduces painful chemotherapy-induced peripheral neuropathy (CIPN). The secondary study endpoint was treatment-r ... Full text Cite